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Background and study aims: Percutaneous placement of fiducial markers is required to perform stereotac-
tic body radiation therapy (SBRT) for liver neoplastic lesions. This prospective trial was designed to eval-
uate the feasibility and safety of percutaneous ultrasound-guided placement of three different types of
markers in patients with liver cancer referred for SBRT.
Patients and methods: Fifty patients underwent percutaneous ultrasound-guided implantation of a fidu-
cial marker in the liver. Three sizes of needles were used: 25 gauge (G), 22 G, and 17 G. The 25 G and 22 G
needles contained gold anchor markers of 0.28  10 mm and 0.4  10 mm size, respectively. In contrast,
the 17 G needle contained a gold grain marker of 1  4 mm. Each patient received 1–6 markers, depend-
ing on lesion size and numbers. Technical feasibility and the occurrence of adverse events were regis-
tered. Computed tomography scans were acquired prior to SBRT to evaluate the location, visibility, or
complications related to the markers.
Results: A total of 163 needles were used to deliver 163 markers in 50 patients. No major complications
occurred. Minor complication occurrence rate was 12%. The total complication occurrence for all type of
markers was 8.5%. No complications were observed with the use of the gold anchor marker of
0.4  10 mm size. Variance analysis of the three markers showed a significant difference in the frequency
of complications amongst the three markers (p < 0.01).
Conclusion: Percutaneous ultrasound-guided placement of fiducial markers for SBRT of liver neoplastic
lesions is safe and feasible. In our series, the 22 G needle showed some advantage in terms of handling
and safety when compared with the 25 G and 17 G needles. In addition, the gold anchor marker of
0.4  10 mm size displayed a lower percentage of displacement.
 2017 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.Introduction
Surgery is the current standard treatment for localised operable
neoplastic lesions of the liver [1]; however, many patients cannot
afford surgical resection because of comorbidities, advanced age,
disease extension, or patients’ wishes. Treatment strategies for
liver cancer have evolved over the last many years. Stereotactic
body radiation therapy (SBRT) using the Cyberknife system is a
non-surgical option for patients with inoperable or surgically com-
plex tumours. In addition, it is an option in the case of absentresponse and/or relapse after chemotherapy and standard radio-
therapy [2]. SBRT administers high doses of radiations that can
reach any anatomic point with a sub-millimetric precision [3,4].
This high accuracy is achieved through a robotic image-guidance
system technology and dynamic tracking of targets, with the
removal of breathing artifacts. Through these techniques, the
CyberKnife system can precisely hit the lesion with high doses of
radiations whilst safeguarding the surrounding critical organs,
which otherwise could be damaged [5,6]. Robotic radiosurgery
can employ different systems for the localisation of the neoplastic
targets for treatment. In particular, for the treatment of the solid
organ tumours, CyberKnife uses a localisation system that is based
on specific gold markers [7]. The placement of a fiducial marker
Fig. 3. Hyperechoic flexible-wire notched gold anchor marker (arrow) near a liver
metastasis.
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motion to be tracked, thus enabling accurate dose delivery whilst
the patient breathes freely [8]. Recently, the percutaneous inser-
tion of fiducial markers has been described [9,10], but experience
with such procedures is limited. The marker is made of gold, which
makes it biocompatible and ensures good contrast on X-ray
images.
The aim of the trial was to evaluate and compare the feasibility
and technical benefits of percutaneous ultrasound (US)-guided
placement of three different types of gold markers in patients with
liver cancer referred for SBRT. We also evaluated the handling and
safety of the three needles of different calibers that were used for
fiducial deployment.
Patients and methods
This was a prospective, single-centre feasibility and compara-
tive study conducted in a tertiary-care medical centre. Eighty
patients affected by neoplastic disease with an indication for
stereotactic radiotherapy were assessed. Thirty of them were
excluded because they were affected by a primitive neoplasia of
the pancreas in absence of liver lesion. Fifty patients affected by
neoplastic liver lesions underwent percutaneous fiducial marker
placement under US guidance. Written informed consent was
obtained from all patients. All procedures were performed by
two expert ultrasonographers using the ProSound Alfa7 (Hitachi-
Aloka, Tokyo, Japan) equipment with a 3.75–7.5-MHz hemispheric
sound technology 91–30 Multi Frequency Convex Abdominal
probe. Local anaesthesia was achieved by the subcutaneous admin-
istration of 1% lidocaine. All gold fiducial markers were placed
under US guidance through sub- or intercostal access. When the
needle tip had reached the target lesion, the fiducial marker was
deployed and the needle removed. We used three different types
of needles: 25 gauge (G), 22 G, and 17 G. The 25 G needle contained
0.28  10 mm gold anchor marker, the 22 G needle contained
0.4  10 mm gold anchor marker, and the 17 G needle contained
the 1  4 mm gold grain marker (Figs. 1 and 2). Every patientFig. 1. Gold anchor marker 0.4  10 mm
Fig. 2. 22-Gaugereceived 1 to 6 fiducial markers depending on the dimension and
the number and location of the liver lesions. The fiducial position-
ing was assessed under US guidance as the marker is easily
detected as a hyperechoic structure (Fig. 3). Seven days after the
procedure, a computed tomography (CT) to identify marker loca-
tion or possible complications was performed for all patients. Sub-
sequently, two months after the SBRT treatment, another CT scan
was performed to evaluate the response to radiotherapy. Technical
success was defined as the successful placement of fiducial mark-
ers at the intended site. Clinical success was defined as the possi-
bility to implement an adequate treatment plan with the
markers retained at the correct position without migration. The
following complications were evaluated: marker migration, mar-
ker shattering, marker not massed, presence of pneumothorax
and/or bleeding, and death. Fiducial migration was defined as seed
dislodgement outside the original injection site, making it unus-
able for guiding SBRT, as determined by CT scan (Fig. 4). All databefore (A) and after massing (B).
fine needle.
Fig. 4. SBRT planning with CT for the simulation of radiation treatment was
performed on all patients to check for marker position and late complications. In
the figure: flexible-wire notched gold anchor marker 0.4  10 mm (arrow).
Table 2
Number and types of markers placed, needles used, and complications. (No.: number).
Type of markers Type of
needle
No. of
complications
No. of Placed
markers placed
Anchor marker 0.28  10 mm 10 17
25 gauge 0
Anchor marker 0.4  10 mm 0 78
22 gauge 1
Grain marker 1  4 mm 4 68
17 gauge 5
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parametric statistical tests such as two-tailed Student t-test, con-
sidering a p-value of <0.05 significant, and one-factor analysis of
variance (ANOVA).Results
Fifty patients (29 men, mean age 63.5 years, range 37–87 years)
who underwent percutaneous US-guided fiducial marker implan-
tation for CyberKnife therapy for liver cancer were enrolled. In
total, 84 liver lesions were evaluated: 6 were primary tumours
and 78 were liver metastases. The mean tumour size was 48 mm
(range 11–150 mm) (Table 1). A total of 163 needles were used,
and 163 gold markers were correctly deployed. Sixty-eight mark-
ers were gold grain type, 78 were gold anchor 0.4  10 mm, and
the remaining 17 were gold anchor 0.28  10 mm. All fiducial
placements were confirmed by US after the procedure. No major
complications related to abdominal puncture occurred during the
placement procedure. One vagal syndrome occurred when using
the 22 G needle (2%), whilst 5 patients developed abdominal pain
following the use of the 17 G needle (10%). No complications were
reported with the use of the 25 G needle. Thus, the total percent of
patients who experienced a minor complication was 12% (6/50).
Following the marker placement, all 50 patients underwent a
simulation CT scan to evaluate the correct fiducial localisation
and any onset of complications. In all the cases, SBRT was consid-
ered possible, and therefore, the clinical success rate was deter-
mined to be 100%. However, only 44 patients underwent SBRT as
the therapy was not performed in 7 patients because of disease
progression (5 patients) or death (2 patients). The presence of a
shattered marker and/or marker not massed was observed in 10
patients with gold anchor markers 0.28  10 mm (25 G needle)
(6%). In addition, intra- or extra-hepatic migration was observed
with 4 gold grain markers 1  4 mm (17 G needle) (2,5%). In con-
trast, no dislocation was observed with the use of the gold anchor
marker 0.4  10 mm (22 G needle). Thus, the total complication
rate related to marker dislocation was 8.5% (14/163) (Table 2).Table 1
Characteristics of patients.
Population characteristics
Male Female Mean age (years) Age range (years) Primary liver tumours
29 21 63.5 37–87 6One-factor ANOVA showed a significant difference in the frequency
of complications with the three different markers (p < 0.01). More
specifically, the gold grain marker showed a significantly greater
number of complications than the other two types of markers
(p < 0.01). Finally, amongst the two types of gold anchor markers,
the 0.28  10 mm type resulted in more number of complications
than the 0.4  10 mm type (p < 0.05).Discussion
SBRT with Cyberknife machine is a new therapeutic option for
tumours that cannot be treated with surgery. Moreover, it provides
an alternative therapeutic option in the case of absent response
and/or relapse after standard treatment [11–14]. The placement
of gold fiducial markers near or inside the tumour is considered
the best tool to improve the accuracy of radio-localisation. Percu-
taneous fiducial marker placement has been widely performed,
but some complications have been reported [15]. In our series,
the gold grain markers showed a higher migration rate than the
gold anchor markers. In addition, the gold anchor marker has an
advantage of greater flexibility and can curl up when pushed
against the parenchyma owing to the spindle and being carried
by the needle. Moreover, its coiled design possibly reduces the
incidence of migration and dislocation. However, our results
showed a higher incidence of complications with 0.28  10 mm
gold anchor markers, probably because of the poor handling of
the 25 G fine needle. In contrast, in our study, no signs of migration
or other complication were observed with the use of the
0.4  10 mm gold anchor marker delivered using the 22 G needle.
This needle is neither flexible nor as thin as the 25 G needle and
therefore is more easily handled, resulting in a more precise and
successful placement. Moreover, the 22 G needle, because of its
small size, might reduce the complication rate related to abdomi-
nal puncture [16].
In conclusion, data in the literature are not concordant with
regards to fiducial marker implantation technique for CyberKnife
therapy. Percutaneous marker placement can be performed under
CT, fluoroscopic, or US guidance, and there are many different
types of gold fiducial markers of different sizes, lengths, and phys-
ical characteristics; therefore, the choice of the placement tech-
nique and type of fiducial markers is challenging. Moreover, the
characteristics of liver lesions, the compliance, and clinical charac-
teristics of the patients should be carefully evaluated to adopt the
appropriate type of fiducial marker and needle for each patient
[17–20]. In this hazy context, our study suggests that the gold
anchor marker of 0.4  10 mm size should be preferred for US-Liver metastases Mean lesions size (mm) Size range of lesions (mm)
78 48 11–150
86 M. Marsico et al. / Arab Journal of Gastroenterology 18 (2017) 83–86guided percutaneous insertion because of its ease of handling and
stability. Moreover, the 22 G needle is optimal for good placement
because of its adequate diameter, which leads to a reduced compli-
cation rate. Furthermore, in accordance with the existing literature,
our study suggests that US-guided fiducial placement is safe and
effective and might represent a valuable and reliable alternative
to CT-guided placement [21–24]. However, our study has limita-
tions such as being a single-centre experience, etherogeneity of
the patient population, and the lack of a randomized design. A ran-
domized prospective trial in a larger cohort is awaited to further
evaluate the superiority of a specific marker over others and eval-
uate the cost-effectiveness of US- versus CT-guided placement.Institutional review board statement and ethical committee
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